MAPS Public Benefit

MAPS Public Benefit Corporation (MAPS PBC) is a wholly-owned subsidiary of Multidisciplinary Association for Psychedelic Studies (MAPS). The special purpose of MAPS PBC is to balance income from the legal sale of MDMA with the social benefits of MAPS' mission by serving as a vehicle for conducting MAPS' psychedelic and marijuana research initiative... s. MAPS PBC's primary work is completing Phase 2 studies of MDMA-assisted psychotherapy for PTSD, and preparing for the Phase 3 clinical trials required to develop MDMA-assisted psychotherapy into an approved treatment for PTSD. MAPS will continue to conduct education and harm reduction projects, to raise funds for MAPS PBC projects, and serve as parent organization and sole funder of MAPS PBC. MAPS PBC was incorporated on December 19, 2014. MAPS PBC is a key part of MAPS' strategy to become a sustainable non-profit organization. MAPS currently projects FDA and European Medicines Agency (EMA) approval for the prescription use of MDMA-assisted psychotherapy for PTSD in 2021. Once MDMA-assisted psychotherapy is approved, MAPS PBC will manage prescription sales of MDMA, a taxable activity that cannot remain inside MAPS' 501(c)(3) designation. Research expenses incurred by MAPS PBC can be used to reduce taxes on income received by MAPS PBC from legal sales of MDMA. Income from prescription sales of MDMA will help fund further research and educational projects in accordance with MAPS' mission, reducing MAPS' reliance on donations over the long term. The MAPS PBC team is led by Amy Emerson (Executive Director/Director of Clinical Research), who has managed MAPS' clinical research programs since 2009. The MAPS' clinical research staff have also joined the MAPS PBC team. The MAPS PBC Board of Directors is appointed by the MAPS Board of Directors, and currently includes Rick Doblin, Ph.D. (MAPS Founder and Executive Director), Allen Hopper (American Civil Liberties Union), and Matt Neal (Amgen).Read More